Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 17/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20506379 | 0.92 | F2 (1.00) | F2KLKB1 | |
| SCHEMBL20506460 | 0.90 | F2 (1.00) | F2KLKB1 | |
| SCHEMBL21748336 | 0.90 | F2 (0.83) | F2KLKB1 | |
| SCHEMBL21748366 | 0.85 | F2 (0.75) | F2KLKB1 | |
| SCHEMBL21748335 | 0.84 | KLKB1 (0.79) | F2KLKB1 | |
| SCHEMBL21748358 | 0.84 | F2 (0.72) | F2KLKB1 | |
| SCHEMBL20506217 | 0.82 | F2 (1.00) | F2KLKB1 | |
| SCHEMBL20506168 | 0.82 | KLKB1 (1.00) | F2KLKB1 | |
| SCHEMBL21748370 | 0.82 | KLKB1 (0.76) | F2KLKB1 | |
| SCHEMBL29905859 | 0.82 | F2 (0.69) | F2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970141-B1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON CORP (US) | 2020-02-26 | — | — | EP | claimed |
| US-9951025-B2 | Halogenopyrazoles as inhibitors of thrombin | VERSEON CORPORATION (US) | 2018-04-24 | — | — | US | claimed |
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-2970141-B1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON CORP (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-2970141-B1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON CORP (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20180186751-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2018-07-05 | — | — | US | disclosed |
| US-9951025-B2 | Halogenopyrazoles as inhibitors of thrombin | VERSEON CORPORATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160046585-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186751-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | F2, TFPI, SERPINC1 | F2 1/4885KLKB1 134/4885 |
| US-20160046585-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | F2, TFPI, SERPINC1 | F2 1/4885KLKB1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.